A Multi-Center, Open-Label, Dose Escalation, Phase 1 Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2018
At a glance
- Drugs PIM 447 (Primary) ; Midazolam
- Indications Multiple myeloma
- Focus Adverse reactions; First in man
- Sponsors Novare Pharmaceuticals; Novartis
- 29 May 2018 Planned End Date changed from 31 Dec 2018 to 27 Dec 2018.
- 23 Mar 2017 Planned End Date changed from 28 Feb 2017 to 31 Dec 2018.
- 23 Mar 2017 Planned primary completion date changed from 28 Feb 2017 to 31 Dec 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History